All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Adult myeloid diseases are a group of clonal diseases that affect the stem cells in bone marrow. Among the adult myeloid diseases, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have high incidence rates of 4 and 3.7 per 100,000 people, respectively. Moreover, the number of MDS cases reaches 40--50 per 100,000 in patients older than 70 years old \[[@pone.0137300.ref001], [@pone.0137300.ref002]\]. The median age at diagnosis is approximately 67 and 76 years for AML and MDS, and the conditions tend to occur earlier in Asian populations \[[@pone.0137300.ref002]--[@pone.0137300.ref005]\]. In addition, men have a significantly higher incidence rate than women \[[@pone.0137300.ref004], [@pone.0137300.ref005]\]. A striking feature of MDS is its genetic instability, and approximately one-third of MDS cases result in AML \[[@pone.0137300.ref002], [@pone.0137300.ref006]--[@pone.0137300.ref010]\]. The pathogenesis of MDS or AML is uncertain, particularly why MDS can transform into AML.

Tobacco is an established factor that can cause carcinogenicity, teratogenicity and mutagenicity. Up to half of current smokers will eventually die of a tobacco-related disease \[[@pone.0137300.ref011]\]. The monograph by the International Agency for Research on Cancer (IARC), the National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines) and the European Society for Medical Oncology Practice Guidelines (ESMO Guidelines) reported that adult myeloid disease is linked to smoking \[[@pone.0137300.ref003], [@pone.0137300.ref010], [@pone.0137300.ref012]\]. Attributable risk calculations suggest that about 15% of all leukemia deaths and 24% of myeloid leukemia deaths are accounted for as a result of cigarette smoking\[[@pone.0137300.ref013]\].

Since the strongest evidence comes from cohort studies, some data were also available from case-control studies. Early in 1978, Paffenbarger \[[@pone.0137300.ref014]\] found that cigarette smoking was related to AML. Many subsequent case-control studies focused on investigating the relationship between cigarette smoking and the risk of AML or MDS, but the results had significant bias \[[@pone.0137300.ref015]--[@pone.0137300.ref018]\]. Fircanis \[[@pone.0137300.ref019]\] evaluated the relationship between smoking and AML, and Tong \[[@pone.0137300.ref020]\] investigated the relationship between smoking and MDS. However, neither of these researchers examined the interrelationship between MDS and AML, wherein approximately one-third of MDS cases transform into AML. Independent analyses of AML or MDS alone cannot accurately assess the association with smoking. In fact, both AML and MDS show identical cellular morphology, clonal hyperplasia of myeloblast. The number of myeloblasts is considered as one of important differential features between them. Myeloblasts are less than 20% in MDS, nevertheless more than 20% in AML \[[@pone.0137300.ref021]\]. We thought that MDS and AML should be grouped together as a single class of "adult myeloid disease" for the purposes of researching pathogenesis, and we herein assessed the relationship between cigarette smoking and the risk of developing adult myeloid disease.

Materials and Methods {#sec006}
=====================

Literature search and study selection {#sec007}
-------------------------------------

A systematic literature search was conducted by two independent reviewers (Wang and Liu) of the PubMed, Cochrane Library, EMBASE and EBSCO databases for papers published from 1990 to 2015. The following search terms were used: (1) "AML" OR "acute myeloid leukemia" or "myelodysplastic syndrome" OR "MDS" OR "myelodysplastic" OR "myelodysplasia" OR "preleukemia"; (2) "smoking" OR "tobacco" OR "cigarette". These search themes were combined using the Boolean operator "and" in several combinations without restrictions. In addition, the references reported in the identified studies were used to complete the search.

Studies eligible for inclusion in this meta-analysis met the following criteria: (1) the study design was a case-control study; (2) investigated the association between smoking and the risk of AML or MDS; (3) the case and control of studies must have been based on adults; (4) the diagnoses of AML and MDS were confirmed either histologically, pathologically, cytologically or by detailed medical records; (5) the odds ratios (OR) and the number of events could be calculated from the data presented;(6) published as a full text document in English. Two reviewers (Liu and Jiang) determined the study eligibility independently. Disagreements were resolved by consensus.

Data extraction and quality assessment {#sec008}
--------------------------------------

Two investigators (Liu and Jiang) read the full text of the manuscripts independently and extracted the following data from each eligible study: first author's name, publication year, country of origin, study period, source of controls, sample size, method of ascertainment of smoking, method of ascertainment of adult myeloid disease and the Newcastle Ottawa Scale (NOS) score \[[@pone.0137300.ref022]\]. The NOS score usually is used for assessing the quality of nonrandomized studies (case-control and cohort studies) in meta-analyses. To assess the quality of these studies, two reviewers (Liu and Jiang) independently read and scored each study according to the NOS \[[@pone.0137300.ref022]\]. NOS scores of 1--3, 4--6, and 7--9 were considered to indicate low, medium and high quality, respectively.

Statistical analysis {#sec009}
--------------------

We calculated the pooled odds ratios (OR) with the 95% CI by using the Comprehensive Meta-Analysis software program (Version 2.2.064 July 27, 2011). The statistical heterogeneity within studies was evaluated using a χ^2^-based Cochran's Q statistic \[[@pone.0137300.ref023]\] and was further quantified using *I* ^*2*^ statistics (*I* ^*2*^ = 0--25%, no heterogeneity; *I* ^*2*^ = 25--50%, moderate heterogeneity; *I* ^*2*^ = 50--75%, large heterogeneity; and *I* ^*2*^ = 75--100%, extreme heterogeneity. For values of *I* ^*2*^ ≤ 50%, the fixed-effects model was used; *I* ^*2*^ ≥ 50%, the random-effects model was used) \[[@pone.0137300.ref023]\]. To investigate the potential heterogeneity, we also conducted a subgroup analysis based on the following four aspects: forms of disease, geographical region, source of controls and the NOS score. Publication bias was examined by Egger's regression and Begger's funnel plot (p ≤ 0.05 was considered to indicate the presence of significant publication bias) \[[@pone.0137300.ref024]\] and was adjusted by Duval and Tweedie's trim-and-fill method \[[@pone.0137300.ref025]\]. A sensitivity analysis was performed to evaluate the potential effects of the removal of one study in each turn. If the outcome was significantly changed after one study was removed, then the study was excluded from the included studies due to selection bias, and a new analysis was conducted.

Results {#sec010}
=======

Literature search {#sec011}
-----------------

There were twenty-five articles included in our meta-analysis \[[@pone.0137300.ref015]--[@pone.0137300.ref018], [@pone.0137300.ref026]--[@pone.0137300.ref046]\]. Two reviewers assessed seventy-six articles independently and excluded fifty-one articles. The reasons for exclusion of the articles were as follows: insufficient data to allow for estimation of the OR for eighteen studies, fourteen studies did not focus on our topic of interest, seven were based on cohort studies, ten were meta-analyses or reviews, and two were included in another article. Our search flow is shown in [Fig 1](#pone.0137300.g001){ref-type="fig"}.

![A flowchart of the study selection process.](pone.0137300.g001){#pone.0137300.g001}

Characteristics of the included studies {#sec012}
---------------------------------------

The main characteristics of the included studies are shown in [Table 1](#pone.0137300.t001){ref-type="table"}. Studies were published from 1990 to 2014. There were ten \[[@pone.0137300.ref016]--[@pone.0137300.ref018], [@pone.0137300.ref030], [@pone.0137300.ref032]--[@pone.0137300.ref035], [@pone.0137300.ref040], [@pone.0137300.ref041]\] studies performed in Europe, ten \[[@pone.0137300.ref026]--[@pone.0137300.ref029], [@pone.0137300.ref036]--[@pone.0137300.ref039], [@pone.0137300.ref045], [@pone.0137300.ref046]\] in North America and five \[[@pone.0137300.ref015], [@pone.0137300.ref031], [@pone.0137300.ref042]--[@pone.0137300.ref044]\] performed in Asia. A total of 8,074 adult myeloid disease cases and 31,805 controls were included in our meta-analysis. The controls of twenty-five studies came from different sources: fourteen \[[@pone.0137300.ref015], [@pone.0137300.ref016], [@pone.0137300.ref018], [@pone.0137300.ref026]--[@pone.0137300.ref029], [@pone.0137300.ref033], [@pone.0137300.ref034], [@pone.0137300.ref036], [@pone.0137300.ref038], [@pone.0137300.ref041], [@pone.0137300.ref045], [@pone.0137300.ref046]\] were population-based, ten \[[@pone.0137300.ref030]--[@pone.0137300.ref032], [@pone.0137300.ref035], [@pone.0137300.ref037], [@pone.0137300.ref039], [@pone.0137300.ref040], [@pone.0137300.ref042]--[@pone.0137300.ref044]\] were hospital-based, and only one \[[@pone.0137300.ref017]\] came from both a population and hospital. Cases in all included studies were confirmed mainly according to one method or several methods combined based on medical records, pathological and cytogenetic findings. Smoking factors were evaluated using the medical records in six \[[@pone.0137300.ref018], [@pone.0137300.ref027], [@pone.0137300.ref031], [@pone.0137300.ref035], [@pone.0137300.ref037], [@pone.0137300.ref044]\] studies, questionnaires in three \[[@pone.0137300.ref015], [@pone.0137300.ref039], [@pone.0137300.ref046]\] studies, personal interviews in twelve \[[@pone.0137300.ref016], [@pone.0137300.ref017], [@pone.0137300.ref028], [@pone.0137300.ref030], [@pone.0137300.ref032], [@pone.0137300.ref034], [@pone.0137300.ref036], [@pone.0137300.ref040]--[@pone.0137300.ref043], [@pone.0137300.ref045]\] studies, telephone interviews in three \[[@pone.0137300.ref026], [@pone.0137300.ref029], [@pone.0137300.ref033]\] studies and one \[[@pone.0137300.ref038]\] study included both a questionnaire and telephone interview. The data about matching were extracted from all of the included studies. According to the Newcastle-Ottawa Scale quality assessment system, sixteen \[[@pone.0137300.ref016], [@pone.0137300.ref017], [@pone.0137300.ref027]--[@pone.0137300.ref029], [@pone.0137300.ref034]--[@pone.0137300.ref036], [@pone.0137300.ref038]--[@pone.0137300.ref043], [@pone.0137300.ref045], [@pone.0137300.ref046]\] studies were high quality (NOS score ≥7), eight \[[@pone.0137300.ref015], [@pone.0137300.ref018], [@pone.0137300.ref026], [@pone.0137300.ref030], [@pone.0137300.ref032], [@pone.0137300.ref033], [@pone.0137300.ref037], [@pone.0137300.ref044]\] studies were medium quality (NOS score ≥4 and ≤6) and one study \[[@pone.0137300.ref031]\] was low quality (NOS = 3). Overall, the average score of all included studies was 6.68.

10.1371/journal.pone.0137300.t001

###### Characteristics of the included studies.

![](pone.0137300.t001){#pone.0137300.t001g}

  Study         Year   Country              Period       Groups    Source of controls   Age (years)       No. of subjects   Adult myeloid disease confirmation                             Smoking evaluation                                     Matching                                                          NOS
  ------------- ------ -------------------- ------------ --------- -------------------- ----------------- ----------------- -------------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------- -----
  Wilson        2014   UK                   1990--2009   Control   PB                   20--79            3417              Medical records                                                Medical records                                        Age, sex, index date                                              6
                                                         MDS                                              849                                                                                                                                                                                                       
  Musselman     2013   USA                  2005--2009   Control   PB                   20--79            692               Cytogenetic results integrated with pathologically confirmed   Self-administered questionnaire                        Age, sex, and BMI                                                 9
                                                         AML                                              414                                                                                                                                                                                                       
  Strom         2012   USA                  2003--2007   Control   PB                   18--80            636               Pathologically confirmed                                       Personal interviews                                    Age, sex, race, county of residence                               7
                                                         AML                                              638                                                                                                                                                                                                       
  Kim           2012   Korea                1997--2008   Control   HB                   50.5±16.9         1700              Pathologically confirmed                                       Medical records                                        Age, sex                                                          5
                                                         AML                                              415                                                                                                                                                                                                       
  Lv            2011   China                2003--2006   Control   HB                   ≥18               806               Pathologically confirmed                                       Face-to-face interviews                                Age, sex                                                          7
                                                         MDS                                              403                                                                                                                                                                                                       
  Wong          2009   China                2003--2007   Control   HB                   ≥18               1444              Pathologically and cytogenetic confirmed                       Personal blinded interviews                            Age, sex                                                          8
                                                         AML                                              722                                                                                                                                                                                                       
  Bjork         2009   Sweden               2001--2004   Control   PB&HB                ≥20               278               Medical records                                                Face-to-face interviews                                Age, sex, county of residence                                     8
                                                         AML                                              104                                                                                                                                                                                                       
                                                         MDS                                              75                                                                                                                                                                                                        
  Richardson    2008   Germany              1986--1998   Control   PB                   53.5±14           266               Medical records                                                Face-to-face interviews                                Year of birth, sex, region                                        8
                                                         ANLL                                             120                                                                                                                                                                                                       
  Pekmezovic    2006   Serbia, Montenegro   2000--2003   Control   HB                   20--85            160               Pathologically confirmed supplemented by medical records       Personal interviews, supplemented by medical records   Age, sex                                                          7
                                                         MDS                                              80                                                                                                                                                                                                        
  Kasim         2005   Canada               1994--1997   Control   PB                   20--74            5039              Pathologically confirmed                                       Mailed questionnaires with telephone follow-up         Age, sex, body mass index                                         8
                                                         AML                                              307                                                                                                                                                                                                       
  Strom         2005   USA                  1999--2003   Control   HB                   24--89            452               Pathologically confirmed                                       Mailed questionnaires                                  Age, sex, ethnicity                                               7
                                                         MDS                                              354                                                                                                                                                                                                       
  Speer         2002   USA                  1984--1993   Control   HB                   Median age (65)   7107              Medical records                                                Medical records                                        Age, sex                                                          5
                                                         AML                                              604                                                                                                                                                                                                       
  Pogoda        2002   USA                  1987--1994   Control   PB                   25--75            412               Pathologically confirmed                                       Non-blinded interviews                                 Birth year, sex, race                                             7
                                                         AML                                              412                                                                                                                                                                                                       
  Dalamaga      2002   Greek                1995--2000   Control   HB                   44--85            84                Pathologically confirmed supplemented by cytogenetic           Medical records                                        Age, sex                                                          7
                                                         MDS                                              84                                                                                                                                                                                                        
  Stagnaro      2001   Italy                1990--1993   Control   PB                   20--74            1779              Pathologically confirmed                                       Blind interviews                                       Age, sex, area of residence, education level, type of interview   8
                                                         AML                                              223                                                                                                                                                                                                       
  Bjork         2001   Sweden               1976--1993   Control   PB                   35--76            351               Pathologically confirmed supplemented by cytogenetic           Structured telephone interview                         Age, sex, county of residence                                     6
                                                         AML                                              333                                                                                                                                                                                                       
  Nisse         2001   France               1991--1996   Control   PB                   62--74            204               Pathologically confirmed                                       Personal interviews                                    Age, sex                                                          7
                                                         MDS                                              204                                                                                                                                                                                                       
  Nagata        1999   Japan                1995--1996   Control   PB                   20--74            830               Pathologically confirmed                                       Mailed questionnaire                                   Sex, region                                                       6
                                                         MDS                                              111                                                                                                                                                                                                       
  West          1995   UK                   NA           Control   HB                   ≥15               399               Pathologically confirmed                                       Personal interviews                                    Age, sex, region, hospital and year of diagnosis                  4
                                                         MDS                                              399                                                                                                                                                                                                       
  Wakabayashi   1994   Japan                1981--1990   Control   HB                   51.3±15.8         150               Medical records                                                Medical records                                        Age, sex                                                          3
                                                         ANLL                                             75                                                                                                                                                                                                        
  Mele          1994   Italy                1986--1989   Control   HB                   ≥30               467               Medical records                                                Personal interviews                                    Age, education, residence                                         6
                                                         AML                                              118                                                                                                                                                                                                       
  Sandler       1993   USA/Canada           1986--1989   Control   PB                   18--79            618               Pathologically confirmed                                       Telephone interviews                                   Age, sex, race, region                                            7
                                                         AML                                              423                                                                                                                                                                                                       
  Brown         1992   USA                  1981--1984   Control   PB                   ≥30               745               Medical records                                                Personal interviews                                    Age, region, vital status                                         9
                                                         ANLL                                             134                                                                                                                                                                                                       
  Brownson      1991   USA                  1984--1990   Control   PB                   ≥20               3641              Pathologically confirmed                                       Medical records                                        Age                                                               7
                                                         AML                                              367                                                                                                                                                                                                       
  Severson      1990   USA                  1984--1986   Control   PB                   20--79            128               Pathologically confirmed                                       Telephone interviews                                   Age, sex, family income                                           5
                                                         ANLL                                             106                                                                                                                                                                                                       

**Abbreviations:** No. of subjects, Number of subjects; MDS, Myelodysplastic Syndrome; AML, Acute Myeloid Leukemia; ANNL, Acute Nonlymphocytic Leukemia; NOS, Newcastle-Ottawa Scale; PB, Population-Based; HB, Hospital-Based; BMI, Body Mass Index.

Meta-analysis {#sec013}
-------------

### Current smokers {#sec014}

Thirteen \[[@pone.0137300.ref015], [@pone.0137300.ref016], [@pone.0137300.ref026], [@pone.0137300.ref028], [@pone.0137300.ref030], [@pone.0137300.ref035], [@pone.0137300.ref037]--[@pone.0137300.ref039], [@pone.0137300.ref041], [@pone.0137300.ref043], [@pone.0137300.ref045], [@pone.0137300.ref046]\] out of fourteen studies independently researched the relationship between MDS or AML and cigarette smoking, and one \[[@pone.0137300.ref017]\] study meanwhile researched MDS and AML. The pooled OR was 1.45 (95% CI, 1.30--1.62; *p*\<0.001), and it was determined that current smokers had a 45% higher risk of developing adult myeloid disease compared with non-smokers, with low heterogeneity ([Fig 2A](#pone.0137300.g002){ref-type="fig"}). A funnel plot identified the presence of publication bias, and Duval and Tweedie's trim-and-fill analysis was used to adjust the ORs ([Fig 2B](#pone.0137300.g002){ref-type="fig"}), with *p* = 0.46 in the Begg rank correction test and p = 0.89 in Egger's linear regression test.

![The odds ratio estimates of the risk of developing adult myeloid disease in smokers.\
(A) A forest plot of the risk of developing adult myeloid disease in current smokers. (B) Duval and Tweedie's trim-and-fill funnel plots were used to observe and adjust the publication bias in current smokers. (C) A forest plot of the risk of developing adult myeloid disease in ever-smokers. (D) Duval and Tweedie's trim-and-fill funnel plots were used to observe and adjust the publication bias in ever-smokers. Among Fig B and D, The white circles represent observed studies, and black circles represent possibly missed studies imputed using Duval and Tweedie's trim-and-fill method. White and black rhombuses represent observed and theoretical combined effect size, respectively.](pone.0137300.g002){#pone.0137300.g002}

### Ever-smokers {#sec015}

Twenty-one \[[@pone.0137300.ref015], [@pone.0137300.ref016], [@pone.0137300.ref018], [@pone.0137300.ref026]--[@pone.0137300.ref030], [@pone.0137300.ref032], [@pone.0137300.ref033], [@pone.0137300.ref035]--[@pone.0137300.ref039], [@pone.0137300.ref041]--[@pone.0137300.ref046]\] out of twenty-two studies independently researched the relationship between MDS or AML and cigarette smoking, and one study \[[@pone.0137300.ref017]\] meanwhile researched MDS and AML. The pooled OR was 1.23 (95% CI, 1.15--1.32; *p*\<0.001), which confirmed that ever-smokers had a 23% increased risk of developing adult myeloid disease compared with non-smokers, with moderate heterogeneity ([Fig 2C](#pone.0137300.g002){ref-type="fig"}). A funnel plot identified the presence of publication bias, so Duval and Tweedie's trim-and-fill analysis was used to adjust the ORs ([Fig 2D](#pone.0137300.g002){ref-type="fig"}), with *p* = 0.75 in the Begg rank correction test and *p* = 0.83 in Egger's linear regression test.

A sensitivity analysis was conducted, and the pooled OR was not significantly changed in the current smokers ([S1 Fig](#pone.0137300.s001){ref-type="supplementary-material"}) or ever-smokers ([S2 Fig](#pone.0137300.s002){ref-type="supplementary-material"}) when individual studies were removed in each turn.

Subgroup analysis {#sec016}
-----------------

We performed subgroup analyses stratified by the forms of disease, geographical region, NOS score (high and medium quality studies) and the source of controls in this study ([Table 2](#pone.0137300.t002){ref-type="table"}).

10.1371/journal.pone.0137300.t002

###### The results of subgroup analyses performed according to the potential sources of heterogeneity.

![](pone.0137300.t002){#pone.0137300.t002g}

  Outcome               Form of disease     Geographical region   NOS score           Source of control                                                                                                       
  --------------------- ------------------- --------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Current smokers**                                                                                                                                                                                         
  No. of datasets       10                  5                     2                   6                   7                   11                  4                   8                   5                   2
  OR (95% CI)           1.49 (1.31--1.69)   1.52 (1.19--1.94)     1.22 (0.85--1.74)   1.31 (1.05--1.63)   1.62 (1.41--1.86)   1.47 (1.30--1.66)   1.62 (1.23--2.14)   1.44 (1.26--1.65)   1.71 (1.37--2.13)   1.32 (0.74--2.34)
  *P value*             \<0.001             0.001                 0.29                0.02                \<0.001             \<0.001             0.001               \<0.001             \<0.001             0.35
  *I* ^*2*^             18%                 0%                    0%                  27%                 0%                  4%                  23%                 20%                 0%                  51%
  Pub. bias             YES                 YES                   CBC                 YES                 YES                 YES                 NO                  YES                 NO                  CBC
  AOR (95% CI)          1.43 (1.27--1.61)   1.48 (1.17--1.86)                         1.09 (0.90--1.31)   1.54 (1.36--1.75)   1.43 (1.27--1.61)                       1.43 (1.25--1.63)                       
  **Ever-smokers**                                                                                                                                                                                            
  No. of datasets       16                  7                     4                   9                   10                  15                  8                   13                  8                   2
  OR (95% CI)           1.21 (1.12--1.31)   1.32 (1.16--1.50)     1.10 (0.95--1.28)   1.24 (1.10--1.40)   1.31 (1.19--1.44)   1.29 (1.19--1.41)   1.16 (0.94--1.43)   1.30 (1.19--1.41)   1.17 (0.97--1.41)   1.16 (0.81--1.66)
  *P value*             \<0.001             \<0.001               0.21                \<0.001             \<0.001             \<0.001             0.01                \<0.001             0.10                0.429
  *I* ^*2*^             37%                 0%                    19%                 0%                  47%                 0%                  60%                 2%                  51%                 0%
  Pub. bias             YES                 NO                    NO                  NO                  YES                 NO                  YES                 NO                  YES                 CBC
  AOR (95% CI)          1.20 (1.11--1.30)                                                                 1.29 (1.17--1.42)                       1.13 (1.01--1.26)                       1.06 (0.88--1.28)   

**Abbreviations:** No. of datasets, Number of datasets (papers); MDS, Myelodysplastic Syndrome; AML, Acute Myeloid Leukemia; Nor A, North America; NOS, Newcastle-Ottawa Scale; Pub. bias, Publication bias; CBC, cannot be calculated; OR, odds ratio; AOR, Adjusted OR; CI, Confidence interval; PB, Population-based; HB, Hospital-based.

### Current smokers {#sec017}

Group stratified by the form of disease showed a pooled OR of 1.43 (95% CI, 1.27--1.61; *p*\<0.001) for AML and 1.48 (95% CI, 1.17--1.86; *p* = 0.001) for MDS ([Fig 3A](#pone.0137300.g003){ref-type="fig"}). When the subjects were grouped by region, the data showed that the pooled OR was 1.22 (95% CI, 0.85--1.74; *p* = 0.29) for Asia, 1.09 (95% CI, 0.90--1.31; *p* = 0.02) for Europe and was 1.54 (95% CI, 1.36--1.75; *p*\<0.001) for North America ([Fig 3B](#pone.0137300.g003){ref-type="fig"}). In the data grouped by the NOS score, it was shown that the pooled OR was 1.43 (95% CI, 1.27--1.61; *p*\<0.001) for high quality studies and was 1.62 (95% CI, 1.23--2.14; *p* = 0.001) for medium quality studies ([Fig 3C](#pone.0137300.g003){ref-type="fig"}). When the data were grouped based on the source of controls, the pooled OR was 1.43 (95% CI, 1.25--1.63; *p*\<0.001) for population-based controls and was 1.71 (95% CI, 1.37--2.13; *p*\<0.001) for hospital-based controls ([Fig 3D](#pone.0137300.g003){ref-type="fig"}).

![Forest plots of the risk of adult myeloid disease in current smokers.\
(A) Forms of disease, (B) geographical region, (C) NOS score (high and medium quality), (D) source of controls.](pone.0137300.g003){#pone.0137300.g003}

### Ever-smokers {#sec018}

The subjects were also grouped based on the form of disease, geographical region, NOS score and source of control, all results indicated an significant increased OR, but a little less than current smokers. The results were shown in [Table 2](#pone.0137300.t002){ref-type="table"} and [Fig 4](#pone.0137300.g004){ref-type="fig"}.

![Forest plots of the risk of adult myeloid disease in ever-smokers.\
(A) Forms of disease, (B) geographical region, (C) NOS score (high and medium quality), (D) source of controls.](pone.0137300.g004){#pone.0137300.g004}

Smoking status analysis {#sec019}
-----------------------

Cigarette smoking does not exert its carcinogenic effects via a single event, but is instead a cumulative process. To further investigate the relationship between cigarette smoking and adult myeloid disease, three aspects were analyzed: the number of cigarettes smoked per day, the number of years of smoking and the pack-years smoked. The outcomes are shown in [Table 3](#pone.0137300.t003){ref-type="table"}. Patients who smoked \< 20 ([Fig 5A](#pone.0137300.g005){ref-type="fig"}) and ≥20 ([Fig 5B](#pone.0137300.g005){ref-type="fig"}) cigarettes per day had 1.24 (95% CI, 1.09--1.40; *p* = 0.001) and 1.32 (95% CI, 1.14--1.53; *p*\<0.001) increased risks of developing adult myeloid disease, respectively. For patients with \<20 ([Fig 5C](#pone.0137300.g005){ref-type="fig"}) and ≥20 ([Fig 5D](#pone.0137300.g005){ref-type="fig"}) years of smoking, the risk of adult myeloid disease was 1.05 (95% CI, 0.90--1.23; *p* = 0.25) and 1.30 (95% CI, 1.16--1.45; *p*\<0.001), respectively. Similarly those with \<20 ([Fig 5E](#pone.0137300.g005){ref-type="fig"}) and ≥20 ([Fig 5F](#pone.0137300.g005){ref-type="fig"}) pack-years had a risk of adult myeloid disease of 1.15 (95% CI, 1.03--1.29; *p* = 0.017) and 1.34 (95% CI, 1.18--1.52; *p*\<0.001), respectively.

10.1371/journal.pone.0137300.t003

###### Odds ratio estimates of the risk of adult myeloid disease according to the smoking status.

![](pone.0137300.t003){#pone.0137300.t003g}

  Outcome           Cigarettes per day   Duration of smoking (years)   Pack-years                                               
  ----------------- -------------------- ----------------------------- ------------------ ------------------ ------------------ ------------------
  No. of datasets   9                    10                            10                 11                 8                  9
  OR (95% CI)       1.24(1.09--1.40)     1.32(1.14--1.53)              1.10(0.93--1.29)   1.30(1.16--1.45)   1.15(1.03--1.29)   1.40(1.23--1.59)
  *p Value*         0.001                \<0.001                       0.25               \<0.001            0.017              \<0.001
  *I* ^*2*^         0%                   18%                           0%                 36%                0%                 20%
  Pub. bias         NO                   NO                            YES                NO                 NO                 YES
  AOR                                                                  1.05(0.90--1.23)                                         1.34(1.18--1.52)

**Abbreviations:** No. of datasets, number of datasets; OR, Odds ratio; AOR, Adjusted OR; CI, Confidence interval; Pub. bias, Publication bias.

![Forest plots of the association of adult myeloid disease with the smoking status based on cigarettes smoked per day (A-B), the duration of smoking (in years) (C-D), and the pack-years smoked (E-F).](pone.0137300.g005){#pone.0137300.g005}

Discussion {#sec020}
==========

Recently, Fircanis \[[@pone.0137300.ref019]\] and Tong \[[@pone.0137300.ref020]\] analyzed association of smoking with AML and MDS by meta-analysis, respectively. Since approximately one-third of MDS cases could progress to AML, we supposed that the inclusion of some transformational cases (where the phenotype was AML but where the disease had developed from MDS) could have induced serious bias in independent analyses. Therefore, we conducted this meta-analysis that combined MDS with AML together as a single class of "adult myeloid disease" to eliminate bias.

To our knowledge, this study is the first meta-analysis that combined MDS with AML to assess the overall risk of adult myeloid disease due to cigarette smoking. We extracted twenty-five studies that included 8,074 cases and 31,805 controls, and demonstrated a statistically significant association between current smoking and an increased incidence of adult myeloid disease. Current smokers were shown to have a 45% higher risk of developing adult myeloid disease than non-smokers. Ever-smokers had a 23% higher risk of developing adult myeloid disease than non-smokers, indicating that current smokers had a higher risk of adult myeloid disease than ever-smokers. One possible reason was that current smokers might have a higher total cumulative dose such as nicotine, benzene and polycyclic aromatic hydrocarbon, and longer exposure time of smoking than ever smokers.

In addition, we found that the risk of myeloid disease had no significant drops after cessationin ever-smokers. As we known, tobacco is one of the most potent carcinogenic mixtures and the carcinogenic effect of cigarette smoking can persist for decades after smoking cessation. Few studies have reported on the dynamics and mechanism following cessation. Most recent two \[[@pone.0137300.ref047], [@pone.0137300.ref048]\] studies showed that DNA methylation levels in ever-smokers approached those of never smokers several years after smoking cessation. Therefore, the DNA methylation maybe one factor that the risk of myeloid disease had no significant drops after cessationin ever-smokers. The truly irreversible nature of smoking-related and associated biomarkers are needed to be investigated.

According to the sub-analysis of the smoking status, there was a dose-relationship between cigarette smoking and adult myeloid disease. First, the risk of adult myeloid disease increased from 24% to 32% when smokers smoked \<20 vs.≥ 20 cigarettes per day. Second, the risk of adult myeloid disease increased from 5% to 30% in smokers who smoked \<20 years compared with those who smoked ≥20 years. Finally, the risk of adult myeloid disease increased from 15% to 34% when the comparison was made of smokers who had smoked \<20 vs.≥ 20 pack-years. Based on these results, we confirmed that there were close, positive, and cumulative effects of smoking on the development of adult myeloid disease. Moreover, we also found that cigarette smoking in North America was associated with a higher ORs than in Europe and Asia, but limited studies were inadequate for a clear conclusion that people who live in North America were susceptible population.

Now that cigarette smoking had a high risk to induce adult myeloid disease, Does it play a key role in MDS transformation? There have as yet been few detailed studies on the MDS transformation into AML by the individuals' smoking habits, however, indirect studies may provide us related clues. Over the years, a large number of studies have been presented that indicate a causal link between MDS development and genetic abnormality, related genes liked *bcl-2* \[[@pone.0137300.ref049]\], *C-CBL* \[[@pone.0137300.ref050]\], *CD95* \[[@pone.0137300.ref051]\], *HOXA9* \[[@pone.0137300.ref052]\], *TNFα* \[[@pone.0137300.ref053]\]. In addition, CpG methylation \[[@pone.0137300.ref054], [@pone.0137300.ref055]\], telomere shortening \[[@pone.0137300.ref056], [@pone.0137300.ref057]\] and microsatellite instability \[[@pone.0137300.ref058]--[@pone.0137300.ref060]\] also were found association with MDS progression to AML. Most importantly all above mentioned factors were affected by cigarette smoking \[[@pone.0137300.ref061]--[@pone.0137300.ref070]\]. Based on these studies, it indirectly indicated that cigarette smoking may be an induced factor on MDS development.

Benzene of smoking is a known clastogen, causing chromosomal aberrations *in vitro*, and prolonged exposure to mean concentrations of \>64 mg/m^3^ may be associated with chromosomal aberrations. In addition, increased risks of developing all types of leukemias were found at all concentrations of exposure, while exposure to levels above 40 ppm increased the risk of acute nonlymphocytic leukemia \[[@pone.0137300.ref071]\]. Zhang \[[@pone.0137300.ref072]\] conducted a chromosome-wide aneuploidy study (CWAS) in workers exposed to benzene, and their findings suggested that the development of aneuploidy may be a potential mechanism underlying benzene-induced leukemia. Benzene is mainly found in the atmosphere, and almost all human exposure is through inhalation (95% of daily intake) \[[@pone.0137300.ref071]\]. Personal exposure assessment research has indicated that an average cigarette smoker inhales 6--10 times the benzene inhaled by average non-smokers, and approximately 90% of a smoker's benzene exposure is from smoking \[[@pone.0137300.ref073]\]. Consequently, the tobacco use may lead to chromosomal and karyotype aberrations due to increased benzene exposure, thus resulting in MDS or AML.

Our study is associated with some limitations that may have affected the results. First, the results were calculated from published studies, and our included studies cannot cover published studies that could have led to a publication bias. In addition, published studies are often positive, and the omission of unpublished studies (with negative findings) may lead to an overestimation of the pooled OR. Second, the methods used to evaluate the smoking habits were mainly questionnaires or reports, rather than based on determinations of the blood levels of cotinine. Third, some of the subset analyses, although specified *a priori*, were performed on small datasets. Finally, methodological differences and confounding factors in the included studies were unavoidable.

Conclusion {#sec021}
==========

In summary, we herein demonstrated that cigarette smoking leads to a significantly increased risk of adult myeloid disease in adults. Cigarette smoking does not act as a carcinogenic factor via a single exposure, and instead leads to a cumulative process. We found that there was a positive risk between smoking and adult myeloid disease when a threshold smoking dose was crossed. More and larger prospective studies should be performed, and future studies should focus on investigating the pathway(s) by which cigarette smoking can induce adult myeloid disease.
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